Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) CEO Daniel Barber sold 25,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the transaction, the chief executive officer owned 627,317 shares of the company’s stock, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Barber also recently made the following trade(s):
- On Tuesday, September 15th, Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock. The stock was sold at an average price of $4.82, for a total transaction of $120,500.00.
Aquestive Therapeutics Stock Down 5.5%
Shares of AQST stock traded down $0.23 during trading hours on Friday, reaching $3.83. 3,672,013 shares of the stock traded hands, compared to its average volume of 2,966,138. Aquestive Therapeutics, Inc. has a 1-year low of $2.93 and a 1-year high of $7.55. The business has a fifty day moving average price of $4.75 and a 200 day moving average price of $4.35. The firm has a market capitalization of $481.33 million, a PE ratio of -5.90 and a beta of 1.49.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. Research analysts expect that Aquestive Therapeutics, Inc. will post -0.50 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AQST. WINTON GROUP Ltd purchased a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $210,000. Engineers Gate Manager LP boosted its stake in shares of Aquestive Therapeutics by 20.5% during the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company’s stock valued at $207,000 after buying an additional 8,496 shares during the period. Wedbush Securities Inc. acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at $60,000. Wellington Management Group LLP boosted its stake in shares of Aquestive Therapeutics by 4.0% during the 2nd quarter. Wellington Management Group LLP now owns 301,647 shares of the company’s stock valued at $1,255,000 after buying an additional 11,587 shares during the period. Finally, Beacon Pointe Advisors LLC purchased a new position in shares of Aquestive Therapeutics during the 2nd quarter valued at $252,000. 32.45% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on AQST shares. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a report on Thursday, September 10th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.60.
Read Our Latest Stock Report on AQST
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations.
Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders.
See Also
- Five stocks we like better than Aquestive Therapeutics
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
